Prevention and management of late renal allograft dysfunction

Journal of Nephrology

Volumn 14, Issue 2, 2001, Pages 71-79

  Serón, Daniel ^a   Moreso, Francesc ^a   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Chronic allograft nephropathy; Clinical trials; Protocol biopsies

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM ANTAGONIST; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS;

CLINICAL PROTOCOL; DIAGNOSTIC PROCEDURE; DIALYSIS; DOSE RESPONSE; DRUG INHIBITION; DYSLIPIDEMIA; GRAFT REJECTION; HEALTH CARE DELIVERY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MEDICAL RESEARCH; METHODOLOGY; NEPHROTOXICITY; ORGAN DONOR; PROPHYLAXIS; RESOURCE ALLOCATION; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

CLINICAL TRIALS; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035010776     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Peeters J, Roels L, Vanrentherghem Y. Chronic renal allograft failure: Clinical overview. Kidney Int 1995; 48 (suppl 52): S97-101.
2. Paul LC, Häyry P. Foegh M, Dennis MJ, Mihatsch MJ, Larsson E, Fellström B. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the fourth Alexis Carrel conference on chronic rejection and accelerated arteriosclerosis in transplanted organs. Transplant Proc 1993; 25: 2022-3.
3. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Fumess P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Häyry PJ, Hill CM, Hoffman EO, Hunsicker LG, Linblad AS, Yamaguchi Y. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-23.
4. Carpenter CB. Long-term failure of transplants: Adding insult to injury. Kidney Int 1995; 48 (suppl 52): S40-4.
5. Cecka JM. The UNOS scientific renal transplant registry. Clin Transpl 1998; 1-16.
6. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 1491-9.
7. Bia MJ. Nonimmunologic causes of late renal graft loss. Kidney Int 1995; 47: 1470-80.
8. Lemström K, Koskinen P, Häyry P. Molecular mechanisms of chronic renal allograft rejection. Kidney Int 1995; 48 (suppl. 52): S2-10.
9. Shirwan H. Chronic allograft rejection. Transplantation 1999; 68: 715-26.
10. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-12.
11. Kasiske BL, Massy ZA, Guijarro C, Ma JZ. Chronic renal allograft rejection and clinical trial design. Kidney Int 1995; 48 (suppl 52): S116-9.
12. Hunsicker LG, Bennet L. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int 1995; 48 (suppl): S120-3.
13. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827-34.
14. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Alderman EL, Schroeder JS, Stinson EB, Brown BW, Valantine HA. Prognostic importance of intimai thickness as measured by intracoronary ultrasounds after cardiac transplantation. Circulation 1995; 92: 3445-52.
15. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med 1993; 328: 164-70.
16. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabat A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
17. Lamich R, Ballester M, Martí V, Brossa V, Aymat R, Carrió I, Berna L, Campreciós M, Puig M, Estorch M, Flotats A, Bordes R, Garcia J, Auge, Padro JM, Caralps JM, Narula J. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol 1998; 32: 413-9.
18. Dimény E, Whalberg J, Larsson E, Fellström B. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995; 9: 79-84.
19. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. Transplantation 1995; 59: 511-4.
20. Serón D, Moreso F, Bover J, Condom E, Gil-Vemet SI, Canas C, Fulladosa X, Torras J, Carrera M, Grinyó JM, Alsina J. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310-6.
21. Legendre C, Thervet E, Skhiri H, Mamzer-Bruneel MF, Cantarovich F, Noel LH, Kreis H. Histologic features of chronic allograft nephropathy by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506-9.
22. Kuypers DRJ, Chapman JR, O'Connell PJ, Allen RDM, Nankivell BJ. Predictors of renal transplant histology at three months. Transplantation 1999; 67: 1222-30.
23. Isoniemi H, Krogerus L, von Willebrand E, Taskinen E, Ahonen J, Häyry P. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155-60.
24. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998, 66: 1736-40.
25. Seron D, Moreso F, Ramón JM, Hueso M, Condom E, Fulladosa X. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 1849-55.
26. Cosio FG, Qiu W, Henry ML, Falkenhain ME, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM. Factors related to the donor organ are major determinants of renal allograft function and survival. Transplantation 1996; 62: 1571-6.
27. Kappel B, Olsen S. Cortical interstitial tissue and sclerosed glomeruli in the normal human kidney, related to age and sex. Virchows Arch A Pathol Ant and Histol 1980, 387: 271-7.
28. Terasaki PL, Gjertson DW, Cecka JM, Takemoto S. Fit and match hypothesis for kidney transplantation. Transplantation 1996; 62: 441-5.
29. Brenner BM, Milford L. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis 1993; 21: 66-71.
30. Moreso F, Serón D, Anunciada AI, Hueso M, Ramon JM, Fulladosa X, Gil-Vemet S, Alsina J, Grinyó JM. Recipient body surface area as a predictor of posttransplant renal allograft evolution. Transplantation 1998: 65: 671-6.
31. Cecka JM, Terasaki PI. Optimal use for older donor kidneys: older recipients. Transplant Proc 1995; 27: 801-4.
32. Murray LA, Reilly JJ, Choudhry M, Durnin JV. A longitudinal study of changes in body composition and basal metabolism in physically active elderly men. Eur J Appl Occupational Physiol 1996; 72: 215-21.
33. Coleman-Musser L, Nelson K, Durand R. Discard rates and transplant outcomes in organs recovered from older donors. J Transpl Coor 1997; 7: 190-4.
34. Johnson LB, Kuo PC, Schweitzer EJ, Ratner LE, Klassen DK, Hoehn-Saric EW, de la Torre A, Weir MR, Strange J, Bartlett S. Double renal allograft successfully increase utilization of kidneys from older donors within a single organ procurement organization. Transplantation 1996; B2: 1581-3.
35. Alfrey EJ, Lee CM, Scandling JD, Pavlakis M, Markezich AJ, Dafoe DC. When should expanded criteria donor kidneys be used for single versus dual transplants. Transplantation 1997; 64: 1142-6.
36. Riera L, Serón D, Franco E, Suarez JF, Fulladosa X, Ramos R, Gil Vemet S, Condom E, Gonzalez C, Grinyó JM, Serrallach N. Double kidney transplant. Transplant Proc 1999; 31: 2287-9.
37. Lu AD, Carter JD, Kuo PC, Johnson L, Rodney T, Stratta R, Chavin K, Ratner L, Bowers VD, Alfrey EJ. Outcome of recipients of dual kidney transplants: analysis of the first 100 registry patients. American Society of Transplant Surgeons. 75 (Abstract), S 561.
38. Remuzzi G, Grinyó J, Ruggenenti P, Bertani M, Cole EH, Milford EL, Brenner BM. Early experience with dual kidney transplantation in adults using expanded donor criteria. J Am Soc Nephrol 1999; 10: 2591-8.
39. Paul LC, Benediktsson H. Post-transplant hypertension and chronic renal allograft rejection. Kidney Int 1995; 48 (suppl. 52): S34-7.
40. Mackenzie HS, Azuma H, Rennke HG, Tilney NL, Brenner BM. Renal mass as a determinant of late allograft outcome: insights from experimental studies in rats. Kidney Int 1995; 48 (suppl 52): S38-42.
41. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplant from spouses and living related donors. N Engl J Med 1995; 333: 333-6.
42. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64: 945-7.
43. Pratschke J, Wilhelm MJ, Kusaka M, Basker M, Cooper DKC, Hancock WW, Tilney N. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 1999; 67: 343-8.
44. Takada M, Nadeau KC, Hancock WW, MacKenzie HS, Shaw GD, Waaga AM, Chandraker A, Sayegh MH, Tilney NL. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1991; 65: 1533-42.
45. Koo DDH, Welsh KI, McLaren AJ, Roake JA, Morris PJ, Fuggle SV. Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999; 56: 1551-9.
46. Troppmann C, Gillingham KJ, Benedetti E, Aldmon PS, Gruessner RW, Najarian JS, Matas AJ. Delayed graft function, acute rejection and outcome after cadaver renal transplantation. A multivariate analysis. Transplantation 1995; 59: 962-8.
47. Troppmann C, Gillingham KJ, Gruessner RW, Dunn DL, Payne WD, Najarian JS, Matas AJ. Delayed graft function in the absence of rejection has no long-term impact. Transplantation 1996; 61: 1331-7.
48. Moreso F, Serón D, Gil-Vernet S, Riera L, Fulladosa X, Ramos B, Alsina J, Grinyó JM. Donor age and delayed graft function as predictors of renal allograft survival in rejection free patients. Nephrol Dial Transplant 1999; 14: 930-5.
49. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66: 1697-701.
50. Yilmaz S, Paavonen T, Häyry P. Chronic rejection of rat renal allografts. The impact of prolonged ischemia time on transplant histology. Transplantation 1992; 53: 823-7.
51. Sola R, Guirado LI, Lopez-Navidad A, Caballero F, Agraz I, Diaz M, Paredes D, Rodriguez S, Vicarra D. Renal transplantation with limit donors. Transplantation 1998; 66: 1159-63.
52. Grinyó JM for the BN 52021 Study Group in Renal Transplantation. BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure. A double blind randomized study. Ann Int Med 1994; 121: 345-7.
53. Land W, Schneeberger H, Schleibner S, Illner D, Abendroth D, Rutilli G, Arfors KE, Messmer K. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57: 211-7.
54. Cecka JM, Cho WV, Terasaki PI. Analysis of the UNOS scientific renal transplant registry at 3 years-early events affecting transplant success. Transplantation 1992; 56: 59-64.
55. Matas AJ. Risk factors for chronic rejection: a clinical perspective. Transplant Immunol 1998; 6: 1-11.
56. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-5.
57. Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Marsh JW, MacCauley J, Johnston J, Randhawa P, Irish W, Gritsch HA, Naraghi R, Hakala TR, Fung JJ, Starzl TE. A prospective, randomized trial of tacrolimus / prednisone versus tacrolimus / prednisone / mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411-5.
58. Kahan BD, Julian BA, Pescovik MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68: 1526-32.
59. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1997; 338: 161-5.
60. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Solillou JP. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8.
61. European Mycophenolate Mofetil Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391-6.
62. Rush DN, Nickerson P, Gough J, McKenna R, Grimm PC, Cheang M, Trpkov K, Solez K, Jeffefy J. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129-34.
63. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-9.
64. Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998, 13 (Suppl 1): 45-9.
65. Isoniemi H, Nurminen M, Tikkanen MJ, von Willebrand E, Krogerus L, Ahonen J, Eklund B, Höckerstedt K, Salmela K, Häyry P. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994; 57: 68-72.
66. Dimény E, Fellström B. Larsson E, Tufveson G, Lithell H. Chronic rascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant 1993; 7: 482-90.
67. Dimény E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellström B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23: 572-9.
68. Massy ZA, Guijarro C, Wiedekehr MR, Ma JC, Kasiske BL. Chronic renal allograft rejection: immunologic and non-immunologic risk factors. Kidney Int 1996; 49: 518-24.
69. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zong HP, Hirata M, Cohen AH, Terasaki PI, Danovitch GM. The effect of pravastatin on acute rejection after kidney transplantation. Transplantation 1996; 61: 1469-74.
70. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosupressive therapy. Kidney Int 1996; 50: 1089-100.
71. Mihatsch MJ, Riffel B, Gudat F. The differential diagnosis of rejection and cyclosporine toxicity. Kidney Int 1995; 48 (Suppl 52): S63-9.
72. Ruiz P, Kolbeck PC, Scroggs MW, Sanfilippo F. Association between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation 1988; 45: 91-5.
73. Dell'Antonio G, Randhawa PS. "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. Transplantation 1999; 67: 484-5.
74. Myers BD, Newton L, Boshkos C, Macoviak JA, Frist WH, Derby GC, Perlroth MG. Chronic injury of human renal microvessels with low dose cyclosporine therapy. Transplantation 1988: 46: 694-703.
75. Almond PS, Matas A, Gillingham KJ, Payne WD, Gores P, Gruessner RW, Najarian JS. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-6.
76. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen DR, Cangro CB, Johnson LB, Kuo PC, Lim JY, Barett ST. A novel approach to the treament of chronic allograft nephropathy. Transplantation 1997, 64: 1706-10.
77. Hueso M, Bover J, Serón D, Gil-Vernet S, Sabaté I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyó JM. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998, 66: 1727-31.
78. Glicklich D, Gupta B, Schurter-Frey G, Greenstein SM, Schechner RS, Tellis VA. Chronic renal allograft rejection. No response to mycophenolate mofetil. Transplantation 1999; 66: 398-9.
79. Azuma H, Tilney NL. Chronic graft rejection. Curr Opin Immunol 1994; 6: 77-6.
80. Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, Morris RE, Robbins RC. Ramacyn reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100: 67-74.
81. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valentine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-15.
82. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 15: 2277-83.
83. Ruggenenti P, Pcrna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
84. Amuchastegui S, Azzollini N, Mister M, Pezzota A, Perico N, Remuzzi G. Chronic allograft nephropathy in the rat improved by angiotensin II receptor blockade but not calcium channel antagonism. J Am Soc Nephrol 1998; 9: 1948-55.
85. Campistol JM, Iñigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, Rivera F. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-9.
86. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999; 10: 1542-9.
87. Fujihara CK, Malheiros DMA, Zatz R, Noronha IL. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-9.